DC Advisory advises Savanne Life Sciences on its majority investment in Franklin Biolabs
Background
- Franklin Biolabs is a new genetic medicines focused contract research organization (CRO) founded by gene therapy pioneer James Wilson (MD, PhD)
- Franklin Biolabs provides specialty services in immunology, vector production and analytics, next generation sequencing and bioinformatics and nonclinical pharmacology / toxicology studies, with a focus on disruptive solutions to advance the gene therapy industry
- Savanne Life Sciences (Savanne) is well-versed in the field of medical research, with a new focus on investing in emerging biotechnology companies, having partnered with premier companies, universities and research institutions
- Savanne is the investment vehicle of Mauritius-based Bioculture Group
Process
- DC Advisory acted as the exclusive financial advisor to Savanne on its majority investment in Franklin Biolabs
- DC Advisory played a pivotal role in supporting Savanne throughout a complex transaction, including assisting the company with conducting thorough due diligence, delivering synergy and standalone cost analyses, and providing comprehensive assistance with planning to ensure smooth operational transition and maximize value creation
Outcome
- In September 2024, Savanne completed its majority investment in Franklin Biolabs
- Backed by Savanne, Franklin Biolabs will support the development of genetic medicines for patients with a wide range of severe disorders by offering access to critical research services
- This transaction demonstrates DC Advisory’s M&A expertise and comprehensive suite of client support capabilities at each step of a transaction within the Healthcare / Life Sciences space
What to read next
Date
Sectors
- Healthcare
Deal type
- M&A Advisory
Deal locations
Deal team
UN SDG Activity
Actions
Disclaimer
For more information, please see our transaction disclaimer
For important information regarding testimonials, please see our disclaimer.